EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Top advances of the year: Myeloproliferative neoplasms

Rupali R Bhave, Ruben Mesa, Michael R Grunwald iD

Cancer · 2023

DOI: 10.1002/cncr.35028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Rupali R Bhave und 2 weiteren Autor:innen. Beteiligte Einrichtung: Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center,…. Hauptthemen laut MEDLINE: Thrombocythemia, Essential, Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid pace of drug development in hematology has led to multiple approvals for myelofibrosis (MF) and polycythemia vera (PV) in recent years. Moreover, there are many innovative agents and combinations being explored for myeloproliferative neoplasms (MPNs). In the past year, there have been several advances in MF, PV, and essential thrombocythemia. In MF, investigational approaches are focusing on strategies to optimize inhibition of signal transduction (including JAK inhibition), modify epigenetics, enhance apoptosis, target DNA replication, transform host immunity, and/or alter the tumor microenvironment. In PV, ropeginterferon alfa‐2b has been introduced to the market in the United States, and data continue to accumulate to support the safety and efficacy of this treatment. Hepcidin mimesis is also emerging as a novel way to treat erythrocytosis. In essential thrombocythemia, ropeginterferon alfa‐2b is being evaluated, as are therapies to modify epigenetics and inhibit CALR. The enhanced focus on MPNs brings hope that our field can improve morbidity and mortality in this group of diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombocythemia, EssentialMyeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisHumansUnited StatesSignal TransductionTumor Microenvironment

Stichwörter der Autor:innen

ETMFMPNPVessential thrombocythemiamyelofibrosismyeloproliferative neoplasmpolycythemia vera

Autor:innen und Institutionen

  • Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, North Carolina, USA.
  • Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.

ORCID-Profile: Michael R Grunwald

Zitieren

APA

Bhave, R. R., Mesa, R., & Grunwald, M. R. (2023). Top advances of the year: Myeloproliferative neoplasms. Cancer. https://doi.org/10.1002/cncr.35028

Vancouver

Bhave RR, Mesa R, Grunwald MR. Top advances of the year: Myeloproliferative neoplasms. Cancer. 2023. doi:10.1002/cncr.35028

BibTeX
@article{Bhave2023,
  author = {Bhave, Rupali R and Mesa, Ruben and Grunwald, Michael R},
  title = {Top advances of the year: Myeloproliferative neoplasms},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.35028}
}
Kostenlos starten →